We presented results from a survey evaluating the utility and user experience of an independent genetic testing and counseling service for hereditary ATTR (hATTR) amyloidosis that is supported by Alnylam – Alnylam Act – at the American College of Medical Genetics and Genomics (ACMG) Annual...

We reported new results from an exploratory analysis of our Phase 1 study with fitusiran, an investigational RNAi therapeutic, in patients with hemophilia A or B with or without inhibitors at the 10th Annual Congress of the European Association of Haemophilia and Allied Disorders (EAHAD) held February 1 – 3, 2017 in Paris, France. [spotlight-link icon="release" href="http://investors.alnylam.com/releasedetail.cfm?ReleaseID=1010213" type=" "]Read our press release[/spotlight-link] [spotlight-link icon="presentation" href="https://www.alnylam.com/web/assets/EAHAD-2017_Management-of-Bleed-Events.pdf" type="(450 KB PDF)"]View the bleed management presentation[/spotlight-link] [spotlight-link icon="presentation" href="https://www.alnylam.com/web/assets/EAHAD-2017_Stability.pdf" type="(690 KB PDF)"]View the stability study presentation[/spotlight-link]

We reported new results from Part C of our Phase 1/2 clinical study of ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 for the treatment of complement-mediated diseases, at the 58th Annual Meeting of the American Society of Hematology (ASH), held December 3 – 6, 2016 in San Diego, California. [spotlight-link icon="release" href="http://investors.alnylam.com/releasedetail.cfm?ReleaseID=1002720" type=" "]Read our press release[/spotlight-link] [spotlight-link icon="presentation" href="https://www.alnylam.com/web/assets/ASH-2016_CC5_Ph-1-Part-C_05Dec2016_CAPELLA.pdf" type="(730 KB PDF)"]View the presentation[/spotlight-link]

We reported positive interim results from our Phase 1 study of fitusiran in patients with hemophilia with inhibitors as well as from our Phase 2 open-label extension (OLE) study in hemophilia patients without inhibitors at the 58th Annual Meeting of the American Society of Hematology (ASH), held December 3 – 6, 2016 in San Diego, California. [spotlight-link icon="release" href="http://investors.alnylam.com/releasedetail.cfm?ReleaseID=1002502" type=" "]Read our press release on hemophilia patients with inhibitors[/spotlight-link] [spotlight-link icon="presentation" href="https://www.alnylam.com/web/assets/ASH-2016_Fitusiran_INHIBITORS_03Dec2016_CAPELLA.pdf" type="(320 KB PDF)"]View the inhibitor presentation[/spotlight-link] [spotlight-link icon="release" href="http://investors.alnylam.com/releasedetail.cfm?ReleaseID=1002510" type=" "]Read our press release on fitusiran Phase 2 OLE [/spotlight-link] [spotlight-link icon="presentation" href="https://www.alnylam.com/web/assets/ASH-2016_Fitusiran_NONINHIBITORS_04Dec2016_CAPELLA2.pdf" type="(460 KB PDF)"]View the Phase 2 OLE presentation[/spotlight-link]

We reported positive initial results from Cohorts 1 and 2 in Part C of our Phase 1 study with givosiran (gi-VOH-si-ran), the International Nonproprietary Name for ALN-AS1, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyrias.  These results were presented at the 58th Annual Meeting of the American Society of Hematology (ASH), held December 3 – 6, 2016 in San Diego, California. [spotlight-link icon="release" href="http://investors.alnylam.com/releasedetail.cfm?ReleaseID=1002501" type=" "]Read our press release[/spotlight-link] [spotlight-link icon="presentation" href="https://www.alnylam.com/web/assets/ASH-2016_Givosiran_Ph-1-Part-C_03Dec2016_CAPELLA.pdf" type="(470 KB PDF)"]View the presentation[/spotlight-link]

We reported interim results from our ongoing EXPLORE study, a multinational, prospective, observational study aimed at characterizing the natural history and clinical management of patients with acute hepatic porphyrias (AHP) who experience recurrent attacks or receive prophylactic treatment to prevent attacks.  Results from 112 patients, of which 104 have acute intermittent porphyria (AIP), showed a mean of 9.5 acute attacks reported in the prior year with severe neuropathic pain as the cardinal feature in 100% of attacks, along with other symptoms including nausea or vomiting (>80%), fatigue (77%), and weakness (79%).  Approximately 64% of patients reported experiencing porphyria symptoms between attacks, with about 46% experiencing symptoms daily.  Patients also reported a diminished quality of life and significant healthcare utilization, with a mean of 4.6 overnight hospitalizations per year (range 0-70) and a mean hospital stay duration of 6.6 days (range 1-60).  Of the attacks reported on study, approximately 76% of them required treatment with heme or at a healthcare facility. [spotlight-link icon="presentation" href="https://www.alnylam.com/web/assets/EXPLORE-AASLD-Slides_11Nov16.pdf" type="(540 KB PDF)"] View the EXPLORE natural history presentation [/spotlight-link]

We presented clinical and non-clinical data in a series of posters and oral presentations at the 12th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), held September 25 - 28, 2016 in Montreal, Quebec. [spotlight-link icon="release" href="http://investors.alnylam.com/releasedetail.cfm?ReleaseID=991334" type=" "]Read our press release[/spotlight-link] [spotlight-link icon="presentation" href="https://www.alnylam.com/web/assets/OTS_ALN-AAT_Phase-1_092816_Final2.pdf" type="(670 KB PDF)"]View the ALN-AAT Phase 1/2 presentation[/spotlight-link] [spotlight-link icon="presentation" href="https://www.alnylam.com/web/assets/GalNAc-siRNA_Nonclinical_Review_092816.pdf" type="(2 MB PDF)"]View the poster on review of non-clinical safety data for GalNAc-siRNAs[/spotlight-link] [spotlight-link icon="presentation" href="https://www.alnylam.com/web/assets/GalNAc-siRNA_vs_ASO_092816.pdf" type="(2 MB PDF)"]View the poster on GalNAc-siRNA vs. GalNAc-ASO[/spotlight-link] [spotlight-link icon="presentation" href="https://www.alnylam.com/web/assets/Cholesterol-siRNA_Muscle_Delivery_092816.pdf" type="(620 KB PDF)"]View the poster on cholesterol conjugates for muscle delivery[/spotlight-link]  

We presented initial clinical data from ALN-GO1, an investigational RNAi therapeutic targeting glycolate oxidase (GO) for the treatment of Primary Hyperoxaluria Type 1 (PH1), at the 17th Congress of the International Pediatric Nephrology Association (IPNA), held September 20 – 24, 2016 in Iguaçu, Brazil. [spotlight-link icon="release" href="http://investors.alnylam.com/releasedetail.cfm?ReleaseID=990764" type=" "]Read our press release[/spotlight-link] [spotlight-link icon="presentation" href="https://www.alnylam.com/web/assets/IPNA_GO1_092416.pdf" type="(970 KB PDF)"]View the presentation[/spotlight-link]

We reported new pre-clinical results in animal models of myasthenia gravis (MG) from ALN-CC5, an investigational RNAi therapeutic in development for the treatment of complement-mediated diseases, at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting, held September 14-17 in New Orleans, Louisiana. [spotlight-link icon="presentation" href="https://www.alnylam.com/web/assets/AANEM_ALN-CC5_MG_Presentation_09142016.pdf" type="(1 MB PDF)"]View the presentation[/spotlight-link]


Receive news and updates on the work at Alnylam that affects you most.